| Title |
Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
|
|---|---|
| Published in |
BMC Cancer, November 2014
|
| DOI | 10.1186/1471-2407-14-887 |
| Pubmed ID | |
| Authors |
Petra Martin, Sinead Noonan, Michael P Mullen, Caitriona Scaife, Miriam Tosetto, Blathnaid Nolan, Kieran Wynne, John Hyland, Kieran Sheahan, Giuliano Elia, Diarmuid O’Donoghue, David Fennelly, Jacintha O’Sullivan |
| Abstract |
Bevacizumab improves progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer patients however currently there are no biomarkers that predict response to this treatment. The aim of this study was to assess if differential protein expression can differentiate patients who respond to chemotherapy and bevacizumab, and to assess if select proteins correlate with patient survival. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 2% |
| Unknown | 46 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 8 | 17% |
| Researcher | 7 | 15% |
| Student > Bachelor | 4 | 9% |
| Student > Doctoral Student | 4 | 9% |
| Other | 4 | 9% |
| Other | 11 | 23% |
| Unknown | 9 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 30% |
| Biochemistry, Genetics and Molecular Biology | 4 | 9% |
| Nursing and Health Professions | 3 | 6% |
| Engineering | 3 | 6% |
| Agricultural and Biological Sciences | 3 | 6% |
| Other | 8 | 17% |
| Unknown | 12 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 November 2014.
All research outputs
#18,384,336
of 22,771,140 outputs
Outputs from BMC Cancer
#5,417
of 8,281 outputs
Outputs of similar age
#262,069
of 361,861 outputs
Outputs of similar age from BMC Cancer
#113
of 165 outputs
Altmetric has tracked 22,771,140 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,281 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,861 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 165 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.